Survivors of Breast Cancer face accelerated aging associated with tumors and treatment

Many breast cancer survivors (BC) are facing accelerated aging, possibly due to the cancer itself or the effects of various treatments.

A recent study at Aging He explored the relationship between the phenotypic acceleration of age (PAA) and the characteristics and BC therapies.

Study: Accelerated aging associated with characteristics and treatments of cancer between surviving breast cancer. Credit Picture: Ground Picture/Shutterstock.com

Import

Breast cancer is the most common cancer among women worldwide. However, early diagnosis and treatment significantly improve survival rates, with five and ten years survival rates at 91% and 85% respectively.

As a result, millions of women live as BC survivors, including four million in the United States.

Despite their extensive life span, BC survivors often face faster cognitive decline and natural weakness than women without cancer. The study used a relatively new measure of aging – Paa -Paa (PAA) – to evaluate biological aging in BC survivors.

PAA is calculated by combining chronological age (CA) with C-rejected protein (CRP, an inflammatory marker) and eight blood biomarkers, providing an cost-effective and affordable way to evaluate aging and predicting the risk of mortality.

Study participants

The study included 1,264 BC. Patients and 429 cancer -free checks. Patients with BC were on average five years older than checks and had twice as much mortality rate (8% vs. 4%) in a median follow -up period.

In diagnosis, 68% of patients were in Stage I or II, while 17% had a stadium III/IV disease. High grade tumors were in 35% of cases, with intermediate tumors at 39%. Almost half (45%) of patients had a positive hormonal receptor but HER2-negative (HR+/HER2-) BC, while 13% had HER2-Intact BC and 14% had a triple negative BC (TNBC).

The treatment varies widely. Surgery was the most common intervention, performed in almost 90% of cases. Chemotherapy was used in 60% of patients, while 51% received radiotherapy and 66% underwent hormone therapy.

Target treatment was administered in 17% of patients, but only 3% received immunotherapy. During the follow -up period, 2% developed a second e.g. and 20% experienced metastasis or relapse.

Study findings

Patients with BC presented higher PAA than checks. In diagnosis, their phenotypic age (PA) exceeded their chronological age (CA) on average four years. This gap was reduced to two years in one year after diagnosis and one year in ten years, with no significant differences in two or five years.

The PAA degree varies based on various factors. Patients diagnosed at the age of 65 and older were initially phenotypically younger than their CA, but over time, age, they were aging faster, surpassing their CA by 1.5 years in two, five and ten years.

Those with stage III/IV BC presented a five -year PAA in the diagnosis, which continued for ten years. High grade tumors were associated with prolonged accelerated aging, culminating in a three -year difference in one year and remain two years higher in the year ten.

Cancer subtypes also affect aging standards. HER2+ patients faster than patients with HR+/HER2, with two -year PAA in the first and 1.5 years in the five -year year.

Patients with TNBC showed an accelerated 3.5 -year aging rate in the first and two years in the second year. However, by the year ten, this trend was reversed and their PA was two years lower than CA.

Impact on treatment on aging

Different ways of treatment had a variety of effects on aging. Surgery seemed to have a protective effect, with patients having a phenotypic age seven years younger than their CA in the year ten. Radiotherapy alone led to a two -year reduction. When both were used together, the impact was similar to that of surgery only.

Chemotherapy and targeted treatment did not significantly affect PAA when they were administered on their own. However, the combination shapes that included chemotherapy led to accelerate aging by four years in a one-year diagnosis.

Patients who received hormonal therapy – either alone or in parallel with chemotherapy and targeted therapy – had almost three years faster than their CA in one and ten years.

Among the chemotherapy factors, alkylosis agents and anthropycines initially increased by two years in the first year. However, this result was reversed over time, leading to a reduction of two to 2.5 years in PA. at five and ten.

In contrast, anti -confirmed, selective estrogen receptor (serms) and aromatase (AIS) inhibitors were initially reduced PA by one year in the second year.

However, the Antimitolites eventually accelerated by aging by seven years a year ten years, while AIS added two years to the same time. These findings indicate that hormonal therapy can contribute to faster aging overall.

Mechanisms of accelerated aging

Accelerated aging in BC survivors can result from multiple factors. Cytotoxic chemotherapy can cause cellular aging, reducing telomeres, chronic inflammation, mitochondrial dysfunction, genomic instability and epigenetic changes. The study shows that these effects can insist even ten years after diagnosis.

Hormone therapy can also play a role by disrupting normal hormonal adaptation, genomic stability and mitochondrial function, leading to germ cell depletion and increased biological aging.

Conclusions

“This study provides evidence to accelerate aging between BC survivors and identifies high -risk populations based on tumor characteristics and treatments.” Specifically, this is the first study applied to PAA based on biochemical indicators and not epigenetic parameters in BC survivors.

However, the findings must be carefully interpreted because of the prejudices of selection and survival. Patients with high grade tumors or aggressive treatments may have higher PAAs, but also higher rates of relapse or death, possibly cant results in the results.

In addition, tumor characteristics mainly affect aging in diagnosis and not during follow -up.

Further research is needed to explore how demographic factors and lifestyle factors interact with the effects of aging of BC survivors, especially with modern therapeutic shapes. These ideas could help improve the long -term care and quality of life of survivors.